08.29.16
BioInvent International has signed an extended contract for manufacturing services with a top global pharmaceutical client for one of its development products. Product details and services were not disclosed. The new agreement is expected to generate about SEK 8 million in revenue, with the majority occurring in 2016.
Michael Oredsson, president and chief executive officer of BioInvent, said, “We are pleased that we have been contracted to provide additional manufacturing services to this major global pharmaceutical client. The extension of our relationship reflects BioInvent’s world-leading expertise in antibody production based around our cGMP-certified facilities, which meet EU and standards.”
BioInvent has recently enhanced its ability to independently produce antibodies following the investment in a single use bioreactor for the development of internal and external projects. BioInvent's production facility has the capacity to produce antibodies,both for research purposes and for clinical trials through to Phase III.